Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results

Area of Science:

• Cardiology
• Pharmacology
• Heart Failure Research

Background:

• Aldosterone receptor antagonists (ARAs) are established treatments for severe heart failure (HF).
• Limited data exists on ARA efficacy in NYHA class II HF patients with reduced ejection fraction.
• Left ventricular (LV) remodeling is a key factor in HF progression.

Purpose of the Study:

• To evaluate the effect of canrenone, an ARA, on LV remodeling in NYHA class II HF.
• To assess changes in LV end-diastolic volume (LVEDV) and ejection fraction (EF) as primary endpoints.
• To investigate secondary endpoints including brain natriuretic peptide (BNP) levels and clinical outcomes.

Main Methods:

• AREA IN-CHF was a randomized, double-blind, placebo-controlled trial.
• 188 patients received canrenone plus optimal HF treatment; 194 received placebo plus optimal treatment.
• 12-month changes in LVEDV, EF, BNP, and a composite endpoint of cardiac death/hospitalization were assessed.

Main Results:

• Canrenone did not significantly alter LVEDV compared to placebo (-18% in both arms).
• Canrenone significantly increased EF (40% to 45%) versus placebo (40% to 43%; P=0.04).
• Canrenone reduced BNP levels (-37% vs. -8%; P<0.0001), left atrial dimensions, and the composite endpoint (8% vs. 15%; P=0.02).

Conclusions:

• Canrenone did not improve LVEDV in NYHA class II HF but enhanced EF and reduced BNP and left atrial size.
• The observed reduction in cardiac death and hospitalization suggests potential clinical benefits.
• Further large-scale trials are warranted to confirm the cardiovascular outcome benefits of canrenone in this patient population.